AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
AXIM BIOTECHNOLOGIES, INC.
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0041 (−56.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
AXIM BIOTECHNOLOGIES, INC. grew revenue 254.6% to $92.90K over the twelve months to Jun 30, 2024. Free cash flow was -$1.03M.
Revenue
$92.90K
+254.6% vs. a year earlier
Operating income
-$2.31M
TTM Q2 2024
Free cash flow
-$1.03M
FY2023
EPS, diluted
-$0.04
FY2023
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2024
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $92.90K
- Net income
- -$4.14M
- EPS, diluted
- -$0.04
- Free cash flow
- -$1.03M
Fourteen years at a glance
Fiscal years 2010 to 2023 and trailing twelve months, USD
Revenue
$92.90K+254.6% YoY
Gross profit
–
Operating income
-$2.31M
Net income
-$4.14M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months